1. Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis
- Author
-
Kathleen Pappritz, Jie Lin, Muhammad El‐Shafeey, Henry Fechner, Uwe Kühl, Alessio Alogna, Frank Spillmann, Ahmed Elsanhoury, Rainer Schulz, Carsten Tschöpe, and Sophie Van Linthout
- Subjects
Mice ,Myocarditis ,Inflammasomes ,NLR Family, Pyrin Domain-Containing 3 Protein ,Disease Progression ,Animals ,Humans ,Colchicine ,Cardiology and Cardiovascular Medicine - Abstract
The acute phase of a coxsackievirus 3 (CVB3)-induced myocarditis involves direct toxic cardiac effects and the systemic activation of the immune system, including the cardiosplenic axis. Consequently, the nucleotide-binding oligomerization domain-like receptor pyrin domain-containing-3 (NLRP3) inflammasome pathway is activated, which plays a role in disease pathogenesis and progression. The anti-inflammatory drug colchicine exerts its effects, in part, via reducing NLRP3 activity, and has been shown to improve several cardiac diseases, including acute coronary syndrome and pericarditis. The aim of the present study was to evaluate the potential of colchicine to improve experimental CVB3-induced myocarditis.C57BL6/j mice were intraperitoneally injected with 1 × 10Colchicine improves LV function in CVB3-induced myocarditis, involving a decrease in cardiac and splenic NLRP3 inflammasome activity, without exacerbation of CVB3 load.
- Published
- 2022
- Full Text
- View/download PDF